Lynparza demonstrated clinically meaningful prolonged survival …
4 days ago · Updated results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall …
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful …
3 days ago · 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm. First and only PARP inhibitor to improve overall survival in early breast cancer
AstraZeneca-Merck Partnered Lynparza Shows Long-Term …
3 days ago · AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza …
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful …
4 days ago · 87.5% of patients treated with LYNPARZA were alive at six-years vs. 83.2% in the comparator arm. ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the …
AstraZeneca says 87.5% of Lynparza-treated patients alive at
3 days ago · In addition, 87.5% of patients treated with LYNPARZA remained alive versus 83.2% of those on placebo. Pick the best stocks and maximize your portfolio:Discover top-rated …
AstraZeneca, Merck report positive long-term data for Lynparza
3 days ago · AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza …
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients …
Mar 16, 2022 · LYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA …
Lynparza and Imfinzi regimen in endometrial cancer
Mar 18, 2024 · Lynparza has a broad clinical trial development programme, and AstraZeneca and MSD are working together to understand how it may affect multiple PARP-dependent tumours …
Lynparza in combination with bevacizumab, and as a …
Sep 9, 2022 · Updated results from the PAOLA-1 Phase III trial demonstrate that Lynparza plus bevacizumab increased median overall survival to 56.5 months versus 51.6 months with …
Lynparza Continues to Benefit in BRCA1/2+, HER2- Breast Cancer
3 days ago · At the time of the updated analysis, there had been 107 (11.6%) deaths in the Lynparza arm and 143 (15.6%) deaths in the placebo arm. The primary cause of death in both …